查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947871

獸醫腫瘤市場分析及預測（至2035年）：依類型、產品、服務、技術、應用、最終使用者、設備、功能及階段分類

Veterinary Oncology Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Device, Functionality, Stage
出版日期: | 出版商: Global Insight Services | 英文 319 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計獸醫腫瘤市場規模將從2024年的17億美元成長到2034年的46億美元，複合年成長率約為11.2%。獸醫腫瘤市場涵蓋動物癌症的診斷和治療，整合了先進的治療方法、診斷技術和支持性護理。寵物飼養率的上升、動物健康意識的增強以及獸醫技術的進步是推動該行業成長的主要因素。標靶治療、免疫療法和精準診斷技術的創新正在推動市場成長，其重點在於提高伴侶動物的存活率和生活品質。對專業腫瘤服務的需求以及不斷擴大的獸醫基礎設施也進一步支撐了該市場的發展潛力。

動物癌症診斷和治療技術的進步正推動獸醫腫瘤市場顯著成長。化療因其療效確切且在獸醫實踐中應用日益廣泛，仍然是成長最快的細分市場。基於分子和基因譜的標靶治療是成長第二快的細分市場，反映了獸醫學向精準醫療的轉變。免疫療法發展勢頭強勁，凸顯了該產業對創新治療方法的投入。包括磁振造影（MRI）和電腦斷層掃描）在內的診斷影像技術對於早期發現和治療方案製定至關重要。寵物保險的日益普及和寵物主人數量的成長進一步推動了市場動態。獸醫醫院和診所正在投資專業的腫瘤服務，以滿足寵物對綜合癌症治療日益成長的需求。獸醫專業人員與製藥公司之間的合作至關重要，有助於開發新型治療方法並改善患者的治療效果。對個人化治療方案的關注有望重塑獸醫腫瘤學的模式。

市場區隔
類型 化療、放射線治療、免疫療法、標靶治療、手術
產品 藥品、生物製藥、放射性藥品及治療性醫療設備
服務 診斷服務、治療服務、諮詢服務和後續觀察護理
科技 分子診斷、影像技術、基因體學、遠端醫療
目的 伴侶動物、家畜、外來動物和野生動物
最終用戶 獸醫診所、動物醫院、研究機構、學術機構
裝置 直線加速器、CT掃描儀、 核磁共振造影系統、PET掃描儀
功能 治療、安寧療護、輔助治療、新輔助治療
階段 早期、中期、晚期、轉移性

獸醫腫瘤市場格局瞬息萬變，市佔率分散在不斷推出創新產品的主要企業之間。定價策略競爭日益激烈，各公司都致力於提供具成本效益的解決方案以提升自身價值主張。新型治療方法和診斷工具的推出正在重塑市場格局，推動著各地區的應用和認可。這些進步在北美和歐洲尤其顯著，這兩個地區的技術整合更為明顯。競爭基準分析顯示，該市場集中度較高，由少數幾家主要企業主導。這些企業持續投資研發以維持其競爭優勢。監管的影響，尤其是在北美和歐洲，在塑造市場動態發揮關鍵作用。嚴格的監管合規確保了產品品質和安全，從而增強了消費者的信任。在寵物主人數量不斷成長和人們對獸醫保健意識提升的推動下，該市場呈現出成長勢頭。策略聯盟和併購可望進一步鞏固市場地位，並提升成長前景。

主要趨勢和促進因素：

受寵物飼養量增加和動物健康意識提升的推動，獸醫腫瘤市場正經歷強勁成長。關鍵趨勢包括先進診斷工具和個人化治療方案的開發，這些都提高了動物癌症治療的準確性和有效性。影像學和分子診斷技術的進步使得早期發現和介入成為可能，從而顯著改善了治療效果。另一個關鍵促進因素是醫療保健基礎設施投資的增加，這主要得益於寵物護理服務的快速擴張，尤其是在新興市場。隨著飼主尋求高品質的寵物護理，對包括腫瘤科在內的專業醫療保健服務的需求也在成長。此外，獸醫遠距醫療平台的興起，使人們更容易接觸到專業的腫瘤專家，並促進獸醫專業人員之間的合作。人工智慧 (AI) 和機器學習在獸醫腫瘤學領域的應用也在不斷推進，為決策和治療方案製定提供數據驅動的洞察。為了滿足全球獸醫腫瘤市場的多樣化需求，能夠提供創新、經濟高效且易於取得的解決方案的公司將擁有眾多發展機會。隨著人們對動物癌症的認知不斷提高，預計該市場將持續擴張，並在已開發地區和發展中地區都具有巨大的成長潛力。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 化療
    • 放射線治療
    • 免疫療法
    • 標靶治療
    • 外科手術
  • 市場規模及預測：依產品分類
    • 製藥
    • 生物製藥
    • 放射性藥物
    • 治療性醫療設備
  • 市場規模及預測：依服務分類
    • 診斷服務
    • 治療服務
    • 體檢服務
    • 後續觀察護理
  • 市場規模及預測：依技術分類
    • 分子診斷
    • 影像診斷
    • 基因組學
    • 遠端醫療
  • 市場規模及預測：依應用領域分類
    • 伴侶動物
    • 家畜
    • 珍稀動物
    • 野生動物
  • 市場規模及預測：依最終用戶分類
    • 獸醫診所
    • 獸醫診所
    • 研究所
    • 學術機構
  • 市場規模及預測：依設備分類
    • 直線加速器
    • CT掃描儀
    • 核磁共振造影系統
    • PET掃描儀
  • 市場規模及預測：依功能分類
    • 治療
    • 寬慰
    • 輔助的
    • 術前協助
  • 市場規模及預測：依疾病階段分類
    • 早期的
    • 中期
    • 晚期
    • 轉移性

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Aratana Therapeutics
  • Vet DC
  • Karyopharm Therapeutics
  • Merial
  • Zoetis
  • Elanco Animal Health
  • Boehringer Ingelheim Animal Health
  • Vetoquinol
  • Ceva Animal Health
  • Dechra Pharmaceuticals
  • Virbac
  • Phibro Animal Health
  • Kindred Biosciences
  • Patterson Veterinary Supply
  • IDEXX Laboratories
  • Heska Corporation
  • Norbrook Laboratories
  • Neogen Corporation
  • Covetrus
  • Immu Cell Corporation

第9章：關於我們

簡介目錄
Product Code: GIS21448

Veterinary Oncology Market is anticipated to expand from $1.7 billion in 2024 to $4.6 billion by 2034, growing at a CAGR of approximately 11.2%. The Veterinary Oncology Market encompasses the diagnosis and treatment of cancer in animals, integrating advanced therapeutics, diagnostics, and supportive care. This sector is driven by rising pet ownership, increased awareness of animal health, and technological advancements in veterinary medicine. Innovations in targeted therapies, immunotherapy, and precision diagnostics are propelling market growth, with a focus on improving survival rates and quality of life for companion animals. The demand for specialized oncology services and the expansion of veterinary healthcare infrastructure further underscore the market's potential.

The Veterinary Oncology Market is experiencing notable growth, fueled by advancements in cancer diagnostics and treatment for animals. Chemotherapy remains the top-performing sub-segment, driven by its established efficacy and expanding adoption in veterinary practices. Targeted therapy, focusing on molecular and genetic profiles, is the second highest performing sub-segment, reflecting a shift towards precision medicine in veterinary care. Immunotherapy is gaining momentum, highlighting the industry's commitment to innovative treatment approaches. Diagnostic imaging, including MRI and CT scans, is essential, enhancing early detection and treatment planning. The rise of pet insurance and increased pet ownership further bolster market dynamics. Veterinary clinics and hospitals are investing in specialized oncology services, catering to the growing demand for comprehensive cancer care in pets. Collaboration between veterinary professionals and pharmaceutical companies is crucial, fostering the development of novel therapeutics and improving patient outcomes. The focus on personalized treatment plans is set to redefine the veterinary oncology landscape.

Market Segmentation
TypeChemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Surgery
ProductPharmaceuticals, Biologics, Radiopharmaceuticals, Therapeutic Devices
ServicesDiagnostic Services, Treatment Services, Consultation Services, Follow-up Care
TechnologyMolecular Diagnostics, Imaging Technologies, Genomics, Telemedicine
ApplicationCompanion Animals, Livestock, Exotic Animals, Wildlife
End UserVeterinary Clinics, Animal Hospitals, Research Institutes, Academic Institutions
DeviceLinear Accelerators, CT Scanners, MRI Machines, PET Scanners
FunctionalityCurative, Palliative, Adjuvant, Neoadjuvant
StageEarly Stage, Mid Stage, Advanced Stage, Metastatic

The Veterinary Oncology Market is characterized by a dynamic landscape where market share is distributed among key players launching innovative products. Pricing strategies are increasingly competitive, with businesses focusing on cost-effective solutions to enhance their offerings. The introduction of novel therapeutics and diagnostic tools is reshaping the market, driving adoption and acceptance across various regions. These advancements are particularly evident in North America and Europe, where technological integration is more pronounced. Competition benchmarking reveals a concentrated market with a few dominant players. These companies are continually investing in research and development to maintain their competitive edge. Regulatory influences, especially in North America and Europe, play a pivotal role in shaping market dynamics. Compliance with stringent regulations ensures product quality and safety, fostering trust among consumers. The market is poised for growth, driven by increasing pet ownership and awareness of veterinary healthcare. Strategic partnerships and mergers are expected to further consolidate market positions, enhancing growth prospects.

Geographical Overview:

The veterinary oncology market is witnessing notable growth across different regions, each presenting unique opportunities. North America leads the market, driven by advanced veterinary healthcare infrastructure and increased pet ownership. The region's focus on research and development in veterinary oncology further propels its market dominance. Europe follows, with a growing awareness of pet health and a robust veterinary care system enhancing market growth. Asia Pacific emerges as a promising market, fueled by rising disposable incomes and an increasing demand for pet healthcare services. Countries like China and India are at the forefront, with expanding veterinary facilities and a growing number of pet owners. Latin America and the Middle East & Africa are also showing potential. In Latin America, the market is bolstered by a rising awareness of animal health, while the Middle East & Africa are recognizing the importance of veterinary oncology in improving animal welfare and health outcomes.

Global tariffs and geopolitical risks are influencing the Veterinary Oncology Market, particularly in East Asia. Japan and South Korea, under trade tensions, are investing in domestic R&D to mitigate reliance on foreign veterinary pharmaceuticals. China is accelerating its focus on indigenous drug development, while Taiwan's pivotal role in biotech innovation is underscored by its geopolitical vulnerabilities. The parent market is robust globally, driven by rising pet ownership and advancements in veterinary care. By 2035, the market is poised for significant growth, contingent on supply chain resilience and regional collaborations. Middle East conflicts are causing fluctuations in energy prices, indirectly affecting manufacturing costs and logistics in these countries, thereby shaping future strategies and market dynamics.

Key Trends and Drivers:

The veterinary oncology market is experiencing robust growth, driven by increasing pet ownership and rising awareness of animal health. Key trends include the development of advanced diagnostic tools and personalized treatment options, which are enhancing the precision and effectiveness of cancer therapies in animals. Technological advancements in imaging and molecular diagnostics are enabling early detection and intervention, significantly improving treatment outcomes. Another significant driver is the growing investment in veterinary healthcare infrastructure, particularly in emerging markets, where pet care services are expanding rapidly. The demand for specialized veterinary services, including oncology, is increasing as pet owners seek high-quality care for their animals. Additionally, the rise of veterinary telemedicine platforms is facilitating access to expert oncologists and fostering collaboration among veterinary professionals. The integration of artificial intelligence and machine learning in veterinary oncology is also gaining traction, offering data-driven insights that aid in decision-making and treatment planning. Opportunities abound for companies that can innovate and provide cost-effective, accessible solutions to meet the diverse needs of the global veterinary oncology market. As awareness of animal cancer rises, the market is poised for sustained expansion, with significant potential for growth in both developed and developing regions.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Chemotherapy
    • 4.1.2 Radiation Therapy
    • 4.1.3 Immunotherapy
    • 4.1.4 Targeted Therapy
    • 4.1.5 Surgery
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Pharmaceuticals
    • 4.2.2 Biologics
    • 4.2.3 Radiopharmaceuticals
    • 4.2.4 Therapeutic Devices
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Diagnostic Services
    • 4.3.2 Treatment Services
    • 4.3.3 Consultation Services
    • 4.3.4 Follow-up Care
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Molecular Diagnostics
    • 4.4.2 Imaging Technologies
    • 4.4.3 Genomics
    • 4.4.4 Telemedicine
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Companion Animals
    • 4.5.2 Livestock
    • 4.5.3 Exotic Animals
    • 4.5.4 Wildlife
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Veterinary Clinics
    • 4.6.2 Animal Hospitals
    • 4.6.3 Research Institutes
    • 4.6.4 Academic Institutions
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Linear Accelerators
    • 4.7.2 CT Scanners
    • 4.7.3 MRI Machines
    • 4.7.4 PET Scanners
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Curative
    • 4.8.2 Palliative
    • 4.8.3 Adjuvant
    • 4.8.4 Neoadjuvant
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Early Stage
    • 4.9.2 Mid Stage
    • 4.9.3 Advanced Stage
    • 4.9.4 Metastatic

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Device
      • 5.2.1.8 Functionality
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Device
      • 5.2.2.8 Functionality
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Device
      • 5.2.3.8 Functionality
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Device
      • 5.3.1.8 Functionality
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Device
      • 5.3.2.8 Functionality
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Device
      • 5.3.3.8 Functionality
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Device
      • 5.4.1.8 Functionality
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Device
      • 5.4.2.8 Functionality
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Device
      • 5.4.3.8 Functionality
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Device
      • 5.4.4.8 Functionality
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Device
      • 5.4.5.8 Functionality
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Device
      • 5.4.6.8 Functionality
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Device
      • 5.4.7.8 Functionality
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Device
      • 5.5.1.8 Functionality
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Device
      • 5.5.2.8 Functionality
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Device
      • 5.5.3.8 Functionality
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Device
      • 5.5.4.8 Functionality
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Device
      • 5.5.5.8 Functionality
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Device
      • 5.5.6.8 Functionality
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Device
      • 5.6.1.8 Functionality
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Device
      • 5.6.2.8 Functionality
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Device
      • 5.6.3.8 Functionality
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Device
      • 5.6.4.8 Functionality
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Device
      • 5.6.5.8 Functionality
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Aratana Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Vet DC
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Karyopharm Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Merial
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Zoetis
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Elanco Animal Health
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Boehringer Ingelheim Animal Health
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Vetoquinol
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Ceva Animal Health
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Dechra Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Virbac
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Phibro Animal Health
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Kindred Biosciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Patterson Veterinary Supply
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 IDEXX Laboratories
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Heska Corporation
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Norbrook Laboratories
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Neogen Corporation
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Covetrus
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Immu Cell Corporation
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us